四环医药(00460.HK)附属自研创新药地罗阿克片获批上市

阿斯达克财经
Aug 24

四环医药(00460.HK) 公布,非全资附属轩竹生物自主研发的ALK抑制剂1类创新药地罗阿克片(商品名:轩菲宁)获中国国家药品监督管理局批准上市,用于治疗间变性淋巴瘤激酶阳性的晚期非小细胞肺癌。这是轩竹生物第三个获批上市的1类创新药,亦第二个获批上市的1类创新肿瘤药。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-08-22 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10